197 related articles for article (PubMed ID: 19610065)
21. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines.
Spitzweg C; Zhang S; Bergert ER; Castro MR; McIver B; Heufelder AE; Tindall DJ; Young CY; Morris JC
Cancer Res; 1999 May; 59(9):2136-41. PubMed ID: 10232600
[TBL] [Abstract][Full Text] [Related]
23. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
[TBL] [Abstract][Full Text] [Related]
24. CCAAT/enhancer-binding protein delta: a molecular target of 1,25-dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells.
Ikezoe T; Gery S; Yin D; O'Kelly J; Binderup L; Lemp N; Taguchi H; Koeffler HP
Cancer Res; 2005 Jun; 65(11):4762-8. PubMed ID: 15930295
[TBL] [Abstract][Full Text] [Related]
25. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells.
Burchardt M; Burchardt T; Shabsigh A; Ghafar M; Chen MW; Anastasiadis A; de la Taille A; Kiss A; Buttyan R
Prostate; 2001 Sep; 48(4):225-30. PubMed ID: 11536301
[TBL] [Abstract][Full Text] [Related]
26. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
Lynch RL; Konicek BW; McNulty AM; Hanna KR; Lewis JE; Neubauer BL; Graff JR
Mol Cancer Res; 2005 Mar; 3(3):163-9. PubMed ID: 15798096
[TBL] [Abstract][Full Text] [Related]
27. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.
Igawa T; Lin FF; Lee MS; Karan D; Batra SK; Lin MF
Prostate; 2002 Mar; 50(4):222-35. PubMed ID: 11870800
[TBL] [Abstract][Full Text] [Related]
28. Development of a prostate-specific promoter for gene therapy against androgen-independent prostate cancer.
Furuhata S; Ide H; Miura Y; Yoshida T; Aoki K
Mol Ther; 2003 Mar; 7(3):366-74. PubMed ID: 12668132
[TBL] [Abstract][Full Text] [Related]
29. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
Chuu CP; Hiipakka RA; Fukuchi J; Kokontis JM; Liao S
Cancer Res; 2005 Mar; 65(6):2082-4. PubMed ID: 15781616
[TBL] [Abstract][Full Text] [Related]
30. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer.
Yang ES; Maiorino CA; Roos BA; Knight SR; Burnstein KL
Mol Cell Endocrinol; 2002 Jan; 186(1):69-79. PubMed ID: 11850123
[TBL] [Abstract][Full Text] [Related]
31. RB activation and repression of C-MYC transcription precede apoptosis of human prostate epithelial cells.
Zhao X; Day ML
Urology; 2001 May; 57(5):860-5. PubMed ID: 11337282
[TBL] [Abstract][Full Text] [Related]
32. Effects of herbal preparation Equiguard on hormone-responsive and hormone-refractory prostate carcinoma cells: mechanistic studies.
Hsieh TC; Lu X; Guo J; Xiong W; Kunicki J; Darzynkiewicz Z; Wu JM
Int J Oncol; 2002 Apr; 20(4):681-9. PubMed ID: 11894110
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets.
Narayanan BA; Narayanan NK; Re GG; Nixon DW
Int J Cancer; 2003 Mar; 104(2):204-12. PubMed ID: 12569576
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of PKCepsilon sensitizes LNCaP human prostate cancer cells to induction of apoptosis by bryostatin 1.
Powell CT; Yin L
Int J Cancer; 2006 Mar; 118(6):1572-6. PubMed ID: 16184549
[TBL] [Abstract][Full Text] [Related]
35. Prostate-specific antitumor activity by probasin promoter-directed p202 expression.
Wen Y; Giri D; Yan DH; Spohn B; Zinner RG; Xia W; Thompson TC; Matusik RJ; Hung MC
Mol Carcinog; 2003 Jul; 37(3):130-7. PubMed ID: 12884364
[TBL] [Abstract][Full Text] [Related]
36. HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling.
Kim YR; Oh KJ; Park RY; Xuan NT; Kang TW; Kwon DD; Choi C; Kim MS; Nam KI; Ahn KY; Jung C
Mol Cancer; 2010 May; 9():124. PubMed ID: 20504375
[TBL] [Abstract][Full Text] [Related]
37. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
Nguyen KH; Hachem P; Khor LY; Salem N; Hunt KK; Calkins PR; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):238-46. PubMed ID: 15993550
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components.
Zhou JR; Yu L; Zhong Y; Nassr RL; Franke AA; Gaston SM; Blackburn GL
Prostate; 2002 Oct; 53(2):143-53. PubMed ID: 12242729
[TBL] [Abstract][Full Text] [Related]
39. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression.
Huang H; Cheville JC; Pan Y; Roche PC; Schmidt LJ; Tindall DJ
J Biol Chem; 2001 Oct; 276(42):38830-6. PubMed ID: 11495901
[TBL] [Abstract][Full Text] [Related]
40. Stromal anti-apoptotic androgen receptor target gene c-FLIP in prostate cancer.
Ye H; Li Y; Melamed J; Pearce P; Wei J; Chiriboga L; Wang Z; Osman I; Lee P
J Urol; 2009 Feb; 181(2):872-7. PubMed ID: 19095249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
